While drugmakers and pharmacy benefit managers have solidified a mutually-beneficial system, it’s not working out so well for patients, Johnson & Johnson Health Care Systems’ Blasine Penkowski said during a recent meeting in Arizona.
According to a Managed Healthcare Executive (MHE) report, Penkowski made the comments during the annual Pharmaceutical Care Management Association meeting.
” … Thanks to recent FDA guidance, manufacturers can begin sharing scientific information even earlier in the process. Better dialogue can help payers and PBMs plan for what’s coming so that patients can have the right therapy at the right time,” Penkowski tells MHE. “This is going to be crucial as cell and gene therapies and other innovative medicines are developed.”
To read the full interview on MHE, click here.